# reload+after+2024-01-20 12:46:40.218900
address1§3960 Howard Hughes Parkway
address2§Suite 500
city§Las Vegas
state§NV
zip§89169
country§United States
phone§917 595 2850
fax§917 595 2851
website§https://pharmacyte.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
fullTimeEmployees§2
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Joshua N. Silverman', 'age': 53, 'title': 'Interim CEO, Interim President & Interim Chairman', 'yearBorn': 1970, 'fiscalYear': 2023, 'totalPay': 197917, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Carlos A. Trujillo CPA, CPA', 'age': 65, 'title': 'Chief Financial Officer', 'yearBorn': 1958, 'fiscalYear': 2023, 'totalPay': 380000, 'exercisedValue': 0, 'unexercisedValue': 840}, {'maxAge': 1, 'name': 'Dr. Jose L. Iglesias M.D.', 'age': 66, 'title': 'Consulting Chief Medical Officer', 'yearBorn': 1957, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hans-Peter  Hammes', 'title': 'Member of Medical & Scientific Advisory Board and Consultant', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.105
currency§USD
dateShortInterest§1702598400
forwardEps§-0.38
exchange§NCM
quoteType§EQUITY
shortName§PharmaCyte  Biotech, Inc.
longName§PharmaCyte Biotech, Inc.
firstTradeDateEpochUtc§1357137000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§986e5578-bcb8-38a3-96b5-8d8402d943ce
gmtOffSetMilliseconds§-18000000
recommendationMean§3.0
recommendationKey§hold
quickRatio§42.72
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
